CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, 4 November 2024 Spexis expects SIX t...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, 29 July 2024 Spexis granted definiti...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, 22 July 2024 Spexis expects that au...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, 8 July, 2024 PARI Pharma GmbH announ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, June 4, 2024 Spexis launches appeal ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 31, 2024   Spexis receives...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 30, 2024 Spexis receives appro...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 17, 2024 Spexis announces exte...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 8, 2024 Spexis announces cl...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, January 15, 2024 Spexis announces sa...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR   Spexis is Granted Debt-Restructuring Moratorium Allsc...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.   Ad hoc announcement pursuant to Art. 53 LR   Spexis Provides Update Regarding Debt-Restru...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 8, 2023 Spexis to file an a...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.   Ad hoc announcement pursuant to Art. 53 LR   Spexis Announces Changes to the Executive Co...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.     Ad hoc announcement pursuant to Art. 53 LR   Spexis provides business update and a...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.     Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 Coli...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic tr...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR     Allschwil, Switzerland, June 26, 2023 Spexis...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 30, 2023   Spexis provides...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 28, 2023 Spexis has received t...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 18, 2023 Spexis announces clos...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 8, 2023   Spexis and ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, January 9, 2023 Spexis reports solid...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, September 22, 2022 Spexis announces positive renal impairment clinical trial res...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, September 06, 2022 Spexis provides business update and announces financial resul...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 28, 2022 Spexis provides busine...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 27, 2022 Spexis Annual General...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 1, 2022 Spexis publishes invit...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, March 24, 2022 Spexis provides busin...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, March 9, 2022 Spexis to present stra...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, March 03rd 2022 Spexis achieves firs...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 30, 2021 Polyphor closes me...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 29, 2021 Polyphor to inform abou...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 15, 2021 Polyphor and EnBio...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, October 29, 2021 Polyphor shareholders approve all resolutions for the planned ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, October 15, 2021 Swiss Takeover Board confirms Absence of an Obligation to make...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, September 27, 2021 Polyphor publishes invitation to Extraordinary General Meetin...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, September 10, 2021 Polyphor and EnBiotix announce closing of purchase agreement ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 1, 2021 Polyphor and EnBio...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, August 3, 2021 Polyphor provides final update on the Phase III FORTRESS study of...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, July 30, 2021 Polyphor to extend period for its strategic evaluation by up to fo...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, July 16, 2021 Polyphor provides update on the future of the FORTRESS study of ba...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, June 28, 2021 Polyphor provides update on the Phase III FORTRESS study of balixa...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, June 8, 2021 Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Nee...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, June 1, 2021 Polyphor's balixafortide demonstrates consistent dual action anti-v...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, May 18, 2021 Polyphor to present at the UBS Global Healthcare Virtual Conference...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, April 6, 2021 Polyphor Annual General Meeting 2021 Polyphor AG (SIX: POLN) toda...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, March 15, 2021 Polyphor publishes invitation to Annual General Meeting 2021 - P...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, March 5, 2021 Polyphor announces financial results for the full-year 2020 - Ph...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, February 26, 2021 Polyphor to Present Full-Year 2020 Financial Results on March ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, January 5, 2021 Polyphor to take part in panel discussion on novel oncology targ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, December 22, 2020 Polyphor receives approval to start first-in-human clinical tr...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, December 14, 2020 Polyphor announces third positive Data Safety Monitoring Board...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, December 11, 2020 Polyphor receives an additional USD 2.3 million award from CAR...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, November 24, 2020 Polyphor receives award of up to USD 3.3 million from Cystic F...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE US Polyphor to Host an Expert Perspectives Webinar o...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, October 29, 2020 Polyphor completes recruitment in Phase III trial of balixafort...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, October 14, 2020 Polyphor receives CARB-X award of up to USD 18.44 million to su...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, September 29, 2020 Polyphor announces closing of Fosun Pharma licensing agreemen...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, September 11, 2020 Polyphor to present at the H.C. Wainwright Global Investment ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, September 3, 2020 Polyphor announces financial results for the first half 2020 ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland and Shanghai, China, August 31, 2020 Polyphor and Fosun Pharma announce exclusiv...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, August 3, 2020 Polyphor announces second positive Data Safety Monitoring Board ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, July 28, 2020 Polyphor strengthens financial flexibility with CHF 19.3 million ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, June 4, 2020 Polyphor shareholders approve all proposals at the Annual General M...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, May 5, 2020 Polyphor publishes invitation to the Annual General Meeting 2020 P...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, April 28, 2020 Polyphor announces financial results for the full-year 2019  ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, March 30, 2020 Polyphor announces positive Data Safety Monitoring Board (DSMB) ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, February 20, 2020 Polyphor announces progress of the Phase III immuno-oncology ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, January 23, 2020 Polyphor appoints Gökhan Batur as Chief Executive Officer ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, November 20, 2019 Polyphor announces changes to its Board of Directors Polyph...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, September 4, 2019 Polyphor announces financial results for the first half 2019 a...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, July 17, 2019 Polyphor closes the Phase III PRISM studies of murepavadin intrave...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, June 27, 2019 Polyphor appoints Frank Weber as new Chief Medical and Development...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, June 20, 2019 Polyphor to present its antibiotic programs at the American Societ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, June 19, 2019 Polyphor announces enrollment of first patient in FORTRESS Phase I...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. MEDIA RELEASE Allschwil, Switzerland, June 7, 2019 Polyphor presents new in-vivo efficacy and tolerabi...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, May 29, 2019 Polyphor and the University of Zurich receive an award from Innosu...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, May 17, 2019 Polyphor announces presentation of new survival data on balixafort...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, May 9, 2019 Polyphor temporarily halts enrollment in the Phase III studies of m...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, April 17, 2019 Polyphor presents new data at ECCMID from its lead antibiotic mu...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, April 16, 2019 Polyphor announces enrollment of first patient in PRISM-UDR - th...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, April 12, 2019 Polyphor's antibiotic murepavadin receives US FDA Qualified Infe...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, April 9, 2019 Polyphor appoints Gökhan Batur as Chief Commercial Officer Polyp...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, March 15, 2019 Polyphor announces financial results for the full-year 2018  ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Polyphor awarded grant from CARB-X of up to $5.6M to support development of novel antibiotic against mult...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, December 3, 2018 Polyphor announces positive results from the FDA Type B Guidan...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, October 24, 2018 Balixafortide combination with eribulin in metastatic breast ca...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, October 24, 2018 Polyphor announces protocol agreement with the FDA for the seco...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, October 24, 2018 CMDO Debra Barker to leave Polyphor; Frank Weber to assist in t...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, September 06, 2018   Polyphor announces financial results for the first hal...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, and Copenhagen, Denmark, September 6, 2018   Novo Holdings invests CHF 6.8 ...

CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Polyphor announces listing of new shares related to the convertible loan facility agreement with the Well...